Last reviewed · How we verify
NCT05613348: CAR19T2
CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
Phase 1, PHASE2 trial testing CD19 CAR T-Cell(CAT19T2) in B-cell Acute Lymphoblastic Leukemia. Withdrawn.
1 December 2025
Quick facts
| Lead sponsor | Zhujiang Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 December 2022 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2028 |
| Sites | 2 locations across China |
Drugs / interventions tested
- CD19 CAR T-Cell(CAT19T2) — full drug profile →
Conditions studied
- B-cell Acute Lymphoblastic Leukemia — all drugs for B-cell Acute Lymphoblastic Leukemia →
- B-Cell Lymphoma, Unspecified — all drugs for B-Cell Lymphoma, Unspecified →
Sponsor
Zhujiang Hospital
Who can join
Adults 1 to 18, any sex, with B-cell Acute Lymphoblastic Leukemia or B-Cell Lymphoma, Unspecified. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the safety and efficacy of humanized Anti-CD19 Chimeric Antigen Receptor-T cell (CAR19T2 T cell) in children with refractory/relapsed B-cell acute lymphoblastic leukemia/lymphoma.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, et al · · 2023 · cited 108× · PMID 38187393 · DOI 10.3389/fimmu.2023.1303935 -
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Saleh K, Pasquier F, Bigenwald C, De Botton S, et al · · 2023 · cited 11× · PMID 37959347 · DOI 10.3390/jcm12216883 -
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?
Vitale C, Griggio V, Perutelli F, Coscia M. · · 2023 · cited 8× · PMID 38044959 · DOI 10.1097/hs9.0000000000000988
Verify or expand the search:
- PubMed search for NCT05613348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-cell Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT06326008 — Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri · Phase 1 · recruiting
- NCT07153796 — A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemoth · Phase 2 · recruiting
- NCT06863259 — Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL · Phase 1 · recruiting
- NCT06793241 — Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
Other Zhujiang Hospital trials
Trials by the same sponsor.
- NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
- NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
- NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05613348 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
- Last refreshed: 18 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05613348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing